Icariin is a PPARα activator inducing lipid metabolic gene expression in mice

Molecules

Volumn 19, Issue 11, 2014, Pages 18179-18191

  Lu, Yuan Fu ^a   Xu, Yun Yan ^a   Jin, Feng ^a   Wu, Qin ^a   Shi, Jing Shan ^a   Liu, Jie ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Clofibrate; Cyp4a14; Icariin; Lipid lowering effect; Mouse live; Ppar

Indexed keywords

ANTIDIABETIC AGENT; FLAVONOID; ICARIIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

AGONISTS; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; LIPID METABOLISM; LIVER; MALE; METABOLISM; MOUSE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIVER; MALE; MICE; PPAR ALPHA;

EID: 84911883752     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191118179     Document Type: Article

References (48)

1. Fruchart, J.C. Peroxisome proliferator-activated receptor-alpha (PPARalpha): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009, 205, 1-8.
2. Seok, H.; Cha, B.S. Refocusing peroxisome proliferator activated receptor-α: A new insight for therapeutic roles in diabetes. Diabetes Metab. J. 2013, 37, 326-332.
3. Duval, C.; Müller, M.; Kersten, S. PPARalpha and dyslipidemia. Biochim. Biophys. Acta 2007, 1771, 961-971.
4. Costet, P.; Legendre, C.; Moré, J.; Edgar, A.; Galtier, P.; Pineau, T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 1998, 273, 29577-29585.
5. Abdelmegeed, M.A.; Yoo, S.H.; Henderson, L.E.; Gonzalez, F.J.; Woodcroft, K.J.; Song, B.J. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J. Nutr . 2011, 141, 603-610.
6. Seedorf, U.; Assmann, G. The role of PPAR alpha in obesity. Nutr. Metab. Cardiovasc. Dis. 2001, 11, 189-194.
7. Gervois, P.; Fruchart, J.C.; Staels, B. Inflammation, dyslipidaemia, diabetes and PPars: Pharmacological interest of dual PPARalpha and PPARgamma agonists. Int. J. Clin. Pract. Suppl. 2004, 143, 22-29.
8. Sze, S.C.; Tong, Y.; Ng, T.B.; Cheng, C.L.; Cheung, H.P. Herba epimedii: Anti-oxidative properties and its medical implications. Molecules 2010, 15, 7861-7670.
9. Kapoor, S. Icariin and its emerging role in the treatment of osteoporosis. Chin. Med. J. 2013, 126, 400-404.
10. Li, L.; Zhou, Q.X.; Shi, J.S. Protective effects of icariin on neurons injured by cerebral ischemia/reperfusion. Chin. Med. J. 2005, 118, 1637-1643.
11. Luo, Y.; Nie, J.; Gong, Q.H.; Lu, Y.F.; Wu, Q.; Shi, J.S. Protective effects of icariin against learning and memory deficits induced by aluminium in rats. Clin. Exp. Pharmacol. Physiol . 2007, 34, 792-795.
12. Xu, R.X; Wu, Q.; Luo, Y.; Gong, Q.H.; Yu, L.M.; Huang, X.N.; Sun, A.S.; Shi, J.S. Protective effects of icariin on cognitive deficits induced by chronic cerebral hypoperfusion in rats. Clin. Exp. Pharmacol. Physiol. 2009, 36, 810-815.
13. Li, F.; Gong, Q.H.; Wu, Q.; Lu, Y.F.; Shi, J.S. Icariin isolated from epimedium brevicornum maxim attenuates learning and memory deficits induced by d-galactose in rats. Pharmacol. Biochem. Behav. 2010, 96, 301-305.
14. Nie, J.; Luo, Y.; Huang, X.N.; Gong, Q.H.; Wu, Q.; Shi, J.S. Icariin inhibits beta-amyloid peptide segment 25-35 induced expression of beta-secretase in rat hippocampus. Eur. J. Pharmacol. 2010, 626, 213-218.
15. Guo, J.; Li, F.; Wu, Q.; Gong, Q.; Lu, Y.; Shi, J. Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats. Phytomedicine 2010, 17, 950-955.
16. Jin, F.; Gong, Q.H.; Xu, Y.S.; Wang, L.N.; Jin, H.; Li, F.; Li, L.S.; Ma, Y.M.; Shi, J.S. Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling. Int. J. Neuropsychopharmacol . 2014, 11, 1-11.
17. Gong, Y.; Shi, J.; Xie, G.Y.; Liu, H.R.; Qi, M.Y. Amelioration of icariin for the epididymis impairment induced by streptozocin (STZ) in rats. Chin. J. Appl. Physiol. 2013, 29, 47-50.
18. Zhang, W.P.; Bai, X.J.; Zheng, X.P.; Xie, X.L.; Yuan, Z.Y. Icariin attenuates the enhanced prothrombotic state in atherosclerotic rabbits independently of its lipid-lowering effects. Planta Med. 2013, 79, 731-736.
19. Xin, H.; Zhou, F.; Liu, T.; Li, G.Y.; Liu, J.; Gao, Z.Z.; Bai, G.Y.; Lu, H.; Xin, Z.C. Icariin ameliorates streptozotocin-induced diabetic retinopathy in vitro and in vivo. Int. J. Mol. Sci. 2012, 13, 866-878.
20. Qi, M.Y.; Chen, K.; Liu, H.R.; Su, Y.H.; Yu, S.Q. Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats. J. Ethnopharmacol. 2011, 138, 731-736.
21. Ding, L.; Liang, X.G.; Zhu, D.Y.; Lou, Y.J. Icariin promotes expression of PGC-1alpha, PPARalpha, and NRF-1 during cardiomyocyte differentiation of murine embryonic stem cells in vitro. Acta Pharmacol. Sin. 2007, 28, 1541-1549.
22. Xu, S.F.; Jin, T.; Lu, Y.F.; Li, L.S.; Liu, J.; Shi, J.S. Effect of icariin on UDP-glucuronosyltransferases in mouse liver. Planta Med. 2014, 80, 387-392.
23. Patsouris, D.; Reddy, J.K.; Müller, M.; Kersten, S. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 2006, 147, 1508-1516.
24. Klaassen, C.D. Learning to program the liver. Annu. Rev. Pharmacol. Toxicol. 2014, 54, 1-8.
25. Guzmán, C.; Benet, M.; Pisonero-Vaquero, S.; Moya, M.; García-Mediavilla, M.V.; Martínez-Chantar, M.L.; González-Gallego, J.; Castell, J.V.; Sánchez-Campos, S.; Jover, R. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down regulation in nonalcoholic fatty liver disease. Biochim. Biophys. Acta 2013, 1831, 803-818.
26. Petrescu, A.D.; Huang, H.; Martin, G.G.; McIntosh, A.L.; Storey, S.M.; Landrock, D.; Kier, A.B.; Schroeder, F. Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARα-regulated β-oxidative enzymes. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304, G241-G256.
27. McIntosh, A.L.; Atshaves, B.P.; Landrock, D.; Landrock, K.K.; Martin, G.G.; Storey, S.M.; Kier, A.B.; Schroeder, F. Liver fatty acid binding protein gene-ablation exacerbates weight gain in high-fat fed female mice. Lipids 2013, 48, 435-448.
28. Krammer, J.; Digel, M.; Ehehalt, F.; Stremmel, W.; Füllekrug, J.; Ehehalt, R. Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. Int. J. Med. Sci. 2011, 8, 599-614.
29. Thering, B.J.; Bionaz, M.; Loor, J.J. Long-chain fatty acid effects on peroxisome proliferator-activated receptor-alpha-regulated genes in Madin-Darby bovine kidney cells: Optimization of culture conditions using palmitate. J. Dairy Sci. 2009, 92, 2027-2037.
30. Rakhshandehroo, M.; Sanderson, L.M.; Matilainen, M.; Stienstra, R.; Carlberg, C.; de Groot, P.J.; Müller, M.; Kersten, S. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res. 2007, 26839, doi:10.1155/2007/26839.
31. Lee, K.; Kerner, J.; Hoppel, C.L. Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex. J. Biol. Chem. 2011, 286, 25655-25662.
32. Puisac, B.; Ramos, M.; Arnedo, M.; Menao, S.; Gil-Rodríguez, M.C.; Teresa-Rodrigo, M.E.; Pié, A.; de Karam, J.C.; Wesselink, J.J.; Giménez, I.; et al. Characterization of splice variants of the genes encoding human mitochondrial HMG-CoA lyase and HMG-CoA synthase, the main enzymes of the ketogenesis pathway. Mol. Biol. Rep. 2012, 39, 4777-4785.
33. Kostiuk, M.A.; Keller, B.O.; Berthiaume, L.G. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARalpha and transcription at the Hmgcs2 PPRE. FASEB J. 2010, 24, 1914-1924.
34. Still, A.J.; Floyd, B.J.; Hebert, A.S.; Bingman, C.A.; Carson, J.J.; Gunderson, D.R.; Dolan, B.K.; Grimsrud, P.A.; Dittenhafer-Reed, K.E.; Stapleton, D.S.; et al. Quantification of mitochondrial acetylation dynamics highlights prominent sites of metabolic regulation. J. Biol. Chem. 2013, 288, 26209-26219.
35. Harano, Y.; Yasui, K.; Toyama, T.; Nakajima, T.; Mitsuyoshi, H.; Mimani, M.; Hirasawa, T.; Itoh, Y.; Okanoue, T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int . 2006, 26, 613-620.
36. De Filippis, B.; Giancristofaro, A.; Ammazzalorso, A.; D'Angelo, A.; Fantacuzzi, M.; Giampietro, L.; Maccallini, C.; Petruzzelli, M.; Amoroso, R. Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism. Eur. J. Med. Chem. 2011, 46, 5218-5224.
37. Huang, H.; McIntosh, A.L.; Martin, G.G.; Petrescu, A.D.; Landrock, K.K.; Landrock, D.; Kier, A.B.; Schroeder, F. Inhibitors of Fatty Acid Synthesis Induce PPAR α-Regulated fatty acid β-oxidative genes: Synergistic roles of L-FABP and glucose. PPAR Res. 2013, 2013, 865604, doi:10.1155/2013/865604.
38. Shi, L.; Shi, L.; Zhang, H.; Hu, Z.; Wang, C.; Zhang, D.; Song, G. Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation. Mol. Med. Rep. 2013, 8, 439-445.
39. Xie, W.D.; Wang, H.; Zhang, J.F.; Li, J.N.; Can, Y.; Qing, L.; Kung, H.F.; Zhang, Y.O. Enhanced peroxisomal β-oxidation metabolism in visceral adipose tissues of high-fat diet-fed obesity-resistant C57BL/6 mice. Exp. Ther. Med. 2011, 2, 309-315.
40. Huang, J.; Zhang, Y.; Zhou, Y.; Zhang, Z.; Xie, Z.; Zhang, J.; Wan, X. Green tea polyphenols alleviate obesity in broiler chickens through the regulation of lipid-metabolism-related genes and transcription factor expression. J. Agric. Food Chem. 2013, 61, 8565-8572.
41. Houten, S.M.; Denis, S.; Argmann, C.A.; Jia, Y.; Ferdinandusse, S.; Reddy, J.K.; Wanders, R.J. Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. J. Lipid Res. 2012, 53, 1296-1303.
42. Kim, M.S.; Lee, K.T.; Iseli, T.J.; Hoy, A.J.; George, J.; Grewal, T.; Roufogalis, B.D. Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver Int . 2013, 33, 1583-1593.
43. Yu, H.L.; Miao, H.T.; Gao, L.F.; Li, L.; Xi, Y.D.; Nie, S.P.; Xiao, R. Adaptive responses by mouse fetus to a maternal HLE diet by downregulating SREBP1: A microarray- and bio-analytic-based study. J. Lipid Res. 2013, 54, 3269-80.
44. Jakobsson, A.; Jörgensen, J.A.; Jacobsson, A. Differential regulation of fatty acid elongation enzymes in brown adipocytes implies a unique role for Elovl3 during increased fatty acid oxidation. Am. J. Physiol. Endocrinol. Metab. 2005, 289, E517-E526.
45. Lin, H.C.; Chen, Y.F.; Hsu, W.H.; Yang, C.W.; Kao, C.H.; Tsai, T.F. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev. Res. 2012, 5, 952-962.
46. Quan, H.Y.; Kim D.Y.; Kim, S.J.; Jo, H.K.; Kim, G.W.; Chung, S.H. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem. Pharmacol. 2013, 85, 1330-1340.
47. Murugesan, S.; Goldberg, E.B.; Dou, E.; Brown, W.J. Identification of diverse lipid droplet targeting motifs in the PNPLA family of triglyceride lipases. PLoS One 2013, 8, e64950.
48. Jha, P.; Claudel, T.; Baghdasaryan, A.; Mueller, M.; Halilbasic, E.; Das, S.K.; Lass, A.; Zimmermann, R.; Zechner, R.; Hoefler, G.; et al. Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. Hepatology 2014, 59, 858-869.